← Leaderboards
Zsu-Zsu Chen
Beth Israel Deaconess Medical Center
$1,517,865
Attributed
$1,517,865
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $859K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,517,865 · 2
By mechanism
K23$823,901 · 1
R01$693,964 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Robert E Gerszten$34,860,502
- Werner Neuhausser$1,376,249
- Ron N Alkalay$3,167,761
- Tracy A. Balboni$1,284,878
- Erin E Kershaw$5,316,895
Research focus
Non-Insulin-Dependent Diabetes MellitusRandomizedGenomic LocusMetforminPathway InteractionsProspectiveFollow-UpGeneticInsightMendelian RandomizationNovel MarkerParticipantPhenotypePlasmaDisease ProgressionEffective TherapyFutureBiological MarkersAdultGlycosylated Hemoglobin AInsulin ResistanceMeasurementCohortRisk Factors
Grant awards (6)
Novel protein biomarkers of youth-onset type 2 diabetes$693,964
R01 · FY2025 · HL · contact PI
Phosphatidylcholine and cholesterol ester biomarkers of type 2 diabetes and preventive treatment effects$165,024
K23 · FY2025 · DK · contact PI
Phosphatidylcholine and cholesterol ester biomarkers of type 2 diabetes and preventive treatment effects$164,471
K23 · FY2024 · DK · contact PI
Phosphatidylcholine and cholesterol ester biomarkers of type 2 diabetes and preventive treatment effects$164,748
K23 · FY2023 · DK · contact PI
Phosphatidylcholine and cholesterol ester biomarkers of type 2 diabetes and preventive treatment effects$163,995
K23 · FY2022 · DK · contact PI
Phosphatidylcholine and cholesterol ester biomarkers of type 2 diabetes and preventive treatment effects$165,663
K23 · FY2021 · DK · contact PI